BioCentury | Apr 12, 2019
Company News

Gilead, Novo team up to combine NASH compounds

...GLP1R) - Glucagon-like peptide-1 receptor Mary Romeo, Staff Writer cenicriviroc (tbr-652, TAK-652) GS-0976, ndi-010976 GS-9674, px-104 oral semaglutide (NN9924, OG217SC) tropifexor, LJN452 Allergan...
BioCentury | Mar 29, 2019
Clinical News

Pfizer's ketohexokinase inhibitor decreases liver fat content in NAFLD Phase II

...he added. Pfizer partnered with Novartis AG (NYSE:NVS; SIX:NOVN) last year to test Novartis' tropifexor (LJN452...
BioCentury | Nov 3, 2018
Product Development

New partners for NASH

...GS‐9674 (p=0.87) and in 12.5% of patients receiving placebo 736 Novartis AG (NYSE:NVS; SIX:NOVN) Tropifexor (LJN452...
...Inc. (NASDAQ:VKTX), San Diego, Calif. Emily Cukier, Senior Writer Aramchol (arachidyl amino cholanoic acid) cenicriviroc (tbr-652, TAK-652) elafibranor (GFT505) IMM-124E, imm124-e LJN452 MB07811...
BioCentury | Nov 2, 2018
Company News

Pfizer, Novartis in NASH deal with multiple MOAs

...Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to test Novartis' tropifexor (LJN452) in combination...
BioCentury | Oct 29, 2018
Company News

Pfizer, Novartis in NASH deal with multiple MOAs

...Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to test Novartis' tropifexor (LJN452) in combination...
BioCentury | Sep 16, 2017
Strategy

Passing the baton

...undisclosed anti-inflammatory/antifibrotic candidate. LJN452 and LMB763 are farnesoid X receptor (FXR; NR1H4) agonists from NIBR. LJN452...
...NASH) and primary bile acid diarrhea. LMB763 is in Phase II for NASH. Novartis expects LJN452...
...in the U.S. and conditional approval in the EU to treat PBC. Narasimhan has said LJN452...
BioCentury | Dec 20, 2016
Company News

Conatus spikes after hours on Novartis NASH deal

...ClinicalTrials.gov, Novartis is recruiting patients for a Phase II trial of non-bile acid FXR agonist LJN452...
Items per page:
1 - 7 of 7